Stephen Chun

Enable Medicine Houston seminar reminder: Catch the session live at the James P. Allison Institute at MD Anderson Cancer Center tomorrow, May 14, starting from 11am CT! Pre-registration in the comments below. Hosted by keynote speaker Alexandro Trevino, PhD, from Enable Medicine, learn how you can make the most of your multimodal #biologicaldata to power the next generation of life-saving diagnostics and therapeutics. 1. Uncover the cutting-edge computational annotation methods and analysis capabilities developed by #machinelearning leaders at Enable Medicine. 2. Explore a comprehensive data-to-insights workflow, including search, mapping, and deep #computationalanalysis, powered by AI on the Enable Medicine platform. 3. Activate your structured, multimodal data to inform critical clinical and #drugdiscovery decisions, from #patientstratification to #indicationselection.

13

2 Comments

Houston, we have liftoff!   The ASCO embargo has lifted on the EpicentRx oral #ASCO24 presentation in Chicago about lead therapy, AdAPT-001.   The presenter is Dr. Anthony Conley, sarcoma specialist and lead investigator on the AdAPT-001 clinical trial from the MD Anderson Cancer Center in Houston, Texas.   This presentation, which takes place from 1:30-1:42 central time in Hall D2 at McCormick Place on June 3rd, 2024, is entitled, “Phase 1/2 study of the TGF-β-trap-enhanced oncolytic adenovirus, AdAPT-001, plus an immune checkpoint inhibitor for patients with immune refractory cancers.”   It is simultaneously broadcast to ASCO online meeting attendees.   One small step up to the ASCO podium will hopefully translate to one giant step for cancer immunotherapy as Dr. Conley shares the very promising, and possibly (fingers crossed 🤞) practice-changing, results with AdAPT-001 + a checkpoint inhibitor in hard-to-treat, immune refractory cancers.

18

Exciting data presented by Dr. Andrew Nixon from Duke Cancer Institute and Dr. Fábio C. P. Navarro from Personalis at #ASCO24! In a study with 33 patients with metastatic esophagogastric cancer (mEGC) treated with pembrolizumab combined with oxaliplatin and capecitabine, NeXT Personal® demonstrated 100% baseline detection. Molecular progression based on ctDNA increases, consistently preceded imaging progression, with a median lead time of 55 days (~2 months). Patients exhibiting an early decrease or clearance in ctDNA levels showed significant improvement in overall survival (OS) (p-value=0.002 and 0.005, respectively) and progression-free survival (PFS) (p-value=0.005 and 0.012, respectively). These results are suggestive that an ultra-sensitive liquid biopsy platform could improve treatment decision-making for patients receiving ICB. Want to learn more about NeXT Personal? Visit us during ASCO at booth 30149. #PrecisionOncology #ctDNA #ImmunoTherapy

80

2 Comments

Infographic of the Day: "Deep Brain Stimulation for #Dystonia" Karen Young, one of Dr. Faisal R. Jahangiri, MD, CNIM, D.ABNM, FASNM, FASET, a graduate student at The University of Texas at Dallas, created this infographic. #ionm #iom #neuromonitoring #neurophysiology #neuroscience #brain #neurosurgery #mapping #language #anesthesia #DBS #deepbrainstimulation

8

Dr. Adit Ginde, lead research investigator and executive committee member for CU Center for COMBAT Research, and his team are making strides to evaluate the efficacy of automatic oxygen therapy technology. Read more about the new study, SAVE-O2 AI. 👇

11

In a recent piece for The Pioneer, Dr. Sudhir Rawal, MBBS, MS, M . Ch, D.N.B. (Urology), and Medical Director and Chief of Genito-Uro Oncology Services, discusses the pivotal role of High-Intensity Focused Ultrasound (HIFU) in treating prostate cancer. Dr. Rawal addresses the pressing issue of prostate cancer in India, noting an alarming estimate of 33,000 to 42,000 new cases each year. A recent study published in The Lancet also predicts a significant rise in cases by 2024. The article offers insights into the various types and symptoms of prostate cancer and explores how HIFU can be an effective treatment option. For more in-depth information, you can read the full article here: https://lnkd.in/giydiC-j Let’s raise awareness and combat cancer together! #ProstateCancerAwareness #HIFU #CancerTreatment #HealthcareInnovation #FightCancer #CancerResearch #MensHealth #Oncology #CancerSurvivor #MedicalAdvances

74

In this cohort study of a colorectal cancer screening program, sequential automated and personalized strategies each were linked to substantial increases in screening completion in all demographic groups. https://ja.ma/3Uj1fg0

1

📢 Editorial Sharing-Vol. 22 No. 6 💕 Title: Neuromyelitis Optica Spectrum Disorder: Redefining an Old Disease. Present and Future Challenges 🤵 Author: Victor Rivera* of Baylor College of Medicine 🔔 Full Text: https://lnkd.in/ei5ha2rV 😎Welcome to your reading! #Parkinsons #ParkinsonsDisease #Neurology #BrainHealth #MovementDisorders #Dopamine #NeurodegenerativeDiseases #Healthcare #Research #Awareness #Treatment #SupportGroups #PatientCare #Therapeutics #MentalHealth #Neuroscience #CureParkinsons #BrainMapping #Neurobiology #BrainInjury #NeuroscienceNews #NeuroImaging

4

🔬 Learn more about the PIVOT-006 Phase 3 randomized clinical trial that explores the potential of cretostimogene for patients with Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (#NMIBC). In this informational video, Dr. Robert Svatek of UT Health San Antonio outlines the open label trial and shares how patients can find more information about the PIVOT-006 study eligibility. 🎥 Watch the informative video here: https://lnkd.in/eDRsXnD8 It is a privilege to collaborate with colleagues like Dr. Svatek and organizations such as the Bladder Cancer Advocacy Network (#BCAN) that share our commitment of advancing #bladdercancer research and improving treatment options for patients following #TURBT. By sharing this post, you are contributing to the support system for those affected and advancing the treatment landscape for NMIBC. 🔎 ClinicalTrials.gov ID: NCT06111235 📧 Contact: recruitment@cgoncology.com  💻 Visit: CGOncology.com/PIVOT-006 🎗️ For more support resources, visit the BCAN website at https://bcan.org. #ClinicalTrials #UrothelialCancer #CancerResearch #MedicalResearch #Urology #Immunotherapy #Therapeutics #BCAN #CGOncology #PIVOT006 #cretostimogene

75

This article discusses the current landscape of CAR T therapies and highlights the potential of a novel BCMA-targeted #oncology treatment. #celltherapy #EPRTalks

2

Hepatitis D is a liver disease caused by infection with hepatitis D virus. This JAMA Patient Page describes hepatitis D infection and its risk factors, outcomes of acute and chronic infection, diagnosis, treatment, and prevention. https://ja.ma/3vWSL4W

82

Most viewed in the last 7 days from JAMA Oncology: This review assesses current evidence and emerging treatment strategies for improved survival among patients with metastatic hormone-sensitive prostate cancer and offers recommendations for clinical practice application. https://ja.ma/3K6lec1

30

Steven Montalvo, M.D., PGY-4 #medicalresident, was recently a guest on At The Beam, a medical education podcast that is focused on #radiationoncology. Listen to Dr. Montalvo speak about the workup and management of #medulloblastoma. https://lnkd.in/dwpyYhti #radiotherapy #cancertreatment #oncology #radiationtherapy  #radiationoncology #cancercare #cancertreatment #braintumor #braincancer #cnscancer

12

📺 Catch Daniel Joyce's, MD, discussion with Sarah Psutka, MD, MSc, at #AUA24 on updates in #KidneyCancer research and how the treatment paradigm is changing as a result of #KEYNOTE564. 🎥 Watch Now:

5

NEW from #ASCO24 | The potential of #ctDNA in monitoring disease progression in #metastatic #colorectalcancer 🎥 Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, discusses the potential of #circulatingtumor (#ctDNA) in monitoring disease progression in #metastaticcolorectalcancer (#mCRC) While acknowledging the promise of #ctDNA, Dr Raghav highlights challenges such as the lack of standardized assays and the need for more randomized #trials to establish appropriate cutoffs and testing intervals. Despite these hurdles, he expresses optimism about the future integration of #ctDNA monitoring into regular #clinicalpractice, emphasizing its potential to enhance precision care in mCRC 🔦 Learn more 👉 https://lnkd.in/eySH6FXm #VJOncology #Oncologynews

4

Hepatitis D is a liver disease caused by infection with hepatitis D virus. This JAMA Patient Page describes hepatitis D infection and its risk factors, outcomes of acute and chronic infection, diagnosis, treatment, and prevention. https://ja.ma/3UISomL

12